Brief: Adamis Pharmaceuticals Provides Update On Clinical Study Assessing Tempol For The Treatment Of Covid-19
01/06/2022 13:21
June 1 (Reuters) - Adamis Pharmaceuticals Corp ADMP.O :
* ADAMIS PHARMACEUTICALS PROVIDES UPDATE ON CLINICAL STUDY
ASSESSING TEMPOL FOR THE TREATMENT OF COVID-19
* ADAMIS PHARMACEUTICALS PROVIDES UPDATE ON CLINICAL STUDY
ASSESSING TEMPOL FOR TREATMENT OF COVID-19
* ADAMIS PHARMACEUTICALS CORP - MEETING OF DSMB OVERSEEING
PHASE
2/3 CLINICAL TRIAL INVESTIGATING USE OF TEMPOL FOR COVID-19, WAS
HELD ON MAY 31
* ADAMIS PHARMACEUTICALS CORP - BASED ON AN INTERIM REVIEW
OF
DATA, DSMB DETERMINED THAT STUDY CAN CONTINUE AS PLANNED
Source text for Eikon: ID:nGNX40QHSZ
Further company coverage: ADMP.O
Recent news on DMK Pharmaceuticals
See all newsBrief: Dmk Pharmaceuticals Corp Says Ebrahim Versi Resigned As Chairman
Brief: ZMI Pharma Finalized Acquisition Of All Strategic Assets Necessary To Manufacture Zimhi From Dmk Pharma
Brief: DMK Pharmaceuticals Files For Chapter 11 Bankruptcy In The U.S. - Court Filing
Brief: Dmk Pharmaceuticals Regains Full Rights To Commercialize Zimhi
Brief: DMK Pharmaceuticals Regains Full Rights From US Worldmeds For Symjepi And Provides Corporate Update